A Multicenter Phase II Study of Local Radiation Therapy for Stage IEA Mucosa-Associated Lymphoid Tissue Lymphomas: A Preliminary Report From the Japan Radiation Oncology Group (JAROG)

Journal Article · Thu Nov 15 04:00:00 EST 2007 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2007.04.029· OSTI ID:21039632

Isobe, Koichi ^[1]; Kagami, Yoshikazu ^[2]; Higuchi, Keiko ^[3]; Kodaira, Takeshi ^[4]; Hasegawa, Masatoshi ^[5]; Shikama, Naoto ^[6]; Nakazawa, Masanori ^[7]; Fukuda, Ichiro ^[8]; Nihei, Keiji ^[9]; Ito, Kana ^[10]; Teshima, Teruki ^[11]; Matsuno, Yoshihiro ^[12]; Oguchi, Masahiko ^[13]

---

1. Department of Radiology, Chiba University Hospital, Chiba (Japan)
2. Radiation Oncology Division, National Cancer Center Hospital, Tokyo (Japan)
3. Department of Radiology, Gunma Prefecture Cancer Center, Gunma (Japan)
4. Department of Radiation Oncology, Aichi Cancer Center Hospital, Aichi (Japan)
5. Department of Radiation Oncology, Nara Medical University, Nara (Japan)
6. Department of Radiology, Shinshu University School of Medicine, Matsumoto (Japan)
7. Department of Radiology, Jichi Medical University, Tochigi (Japan)
8. Department of Radiology, Jikei University School of Medicine, Tokyo (Japan)
9. Radiation Oncology Division, National Cancer Center Hospital East, Chiba (Japan)
10. Department of Radiology, Juntendo University School of Medicine, Tokyo (Japan)
11. Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Osaka (Japan)
12. Clinical Laboratory Division, National Cancer Center Hospital, Tokyo (Japan)
13. Department of Radiologic Oncology, Cancer Institute Hospital, Tokyo (Japan)

Purpose: The aim of this study was to evaluate the efficacy and toxicity of moderate dose radiation therapy (RT) for mucosa-associated lymphoid tissue (MALT) lymphoma in a prospective multicenter phase II trial. Methods and Materials: The subjects in this study were 37 patients with MALT lymphoma between April 2002 and November 2004. There were 16 male and 21 female patients, ranging in age from 24 to 82 years, with a median of 56 years. The primary tumor originated in the orbit in 24 patients, in the thyroid and salivary gland in 4 patients each, and 5 in the others. The median tumor dose was 30.6 Gy (range, 30.6-39.6 Gy), depending on the primary site and maximal tumor diameter. The median follow-up was 37.3 months. Results: Complete remission (CR) or CR/unconfirmed was achieved in 34 patients (92%). The 3-year overall survival, progression-free survival, and local control probability were 100%, 91.9%, and 97.3%, respectively. Thirteen patients experienced Grade 1 acute toxicities including dermatitis, mucositis, and conjunctivitis. One patient developed Grade 2 taste loss. Regarding late toxicities, Grade 2 reactions including hypothyroidism, and radiation pneumonitis were observed in three patients, and Grade 3 cataract was seen in three patients. Conclusions: This prospective phase II study demonstrated that moderate dose RT was highly effective in achieving local control with acceptable morbidity in 37 patients with MALT lymphoma.

• OSTI ID: 21039632
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 69; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CATARACTS
CONJUNCTIVITIS
DERMATITIS
HYPOTHYROIDISM
LYMPHOMAS
MUCOUS MEMBRANES
PATIENTS
PNEUMONITIS
RADIATION DOSES
RADIOTHERAPY
SALIVARY GLANDS
THYROID
TOXICITY